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Abstract
Background: We and others have demonstrated previously that ghrelin receptor (GhrR) knock out (KO) mice fed a
high fat diet (HFD) have increased insulin sensitivity and metabolic flexibility relative to WT littermates. A striking
feature of the HFD-fed GhrR KO mouse is the dramatic decrease in hepatic steatosis. To characterize further the
underlying mechanisms of glucose homeostasis in GhrR KO mice, we conducted both hyperglycemic (HG) and
hyperinsulinemic-euglycemic (HI-E) clamps. Additionally, we investigated tissue glucose uptake and specifically
examined liver insulin sensitivity.
Results: Consistent with glucose tolerance-test data, in HG clamp experiments, GhrR KO mice showed a reduction
in glucose-stimulated insulin release relative to WT littermates. Nevertheless, a robust 1
st phase insulin secretion
was still achieved, indicating that a healthy b-cell response is maintained. Additionally, GhrR KO mice demonstrated
both a significantly increased glucose infusion rate and significantly reduced insulin requirement for maintenance
of the HG clamp, consistent with their relative insulin sensitivity. In HI-E clamps, both LFD-fed and HFD-fed GhrR
KO mice showed higher peripheral insulin sensitivity relative to WT littermates as indicated by a significant increase
in insulin-stimulated glucose disposal (Rd), and decreased hepatic glucose production (HGP). HFD-fed GhrR KO
mice showed a marked increase in peripheral tissue glucose uptake in a variety of tissues, including skeletal
muscle, brown adipose tissue and white adipose tissue. GhrR KO mice fed a HFD also showed a modest, but
significant decrease in conversion of pyruvate to glucose, as would be anticipated if these mice displayed
increased liver insulin sensitivity. Additionally, the levels of UCP2 and UCP1 were reduced in the liver and BAT,
respectively, in GhrR KO mice relative to WT mice.
Conclusions: These results indicate that improved glucose homeostasis of GhrR KO mice is characterized by robust
improvements of glucose disposal in both normal and metabolically challenged states, relative to WT controls.
GhrR KO mice have an intact 1
st phase insulin response but require significantly less insulin for glucose disposal.
Our experiments reveal that the insulin sensitivity of GhrR KO mice is due to both BW independent and dependent
factors. We also provide several lines of evidence that a key feature of the GhrR KO mouse is maintenance of
hepatic insulin sensitivity during metabolic challenge.
Background
Administration of exogenous acyl-ghrelin peptide causes
insulin resistance in humans [1]. Consistent with this
observation, mice with genetic blockade of ghrelin sig-
naling resist diet-induced obesity and show evidence of
improved glucose homeostasis under this metabolic
stress [2-5]. Pharmacologic antagonism of the ghrelin
receptor suppresses appetite, promotes weight loss and
improves glucose tolerance [6,7]. Overall, these studies
provide compelling evidence that ghrelin and its recep-
tor play an important role in regulation of glucose
homeostasis. However, the mechanism[s] linking
improved insulin sensitivity and ghrelin signaling are
still under investigation.
Circulating ghrelin levels are modulated by changes in
nutritional status, such as food deprivation [8] or expo-
sure to HFD [9,10]. Similarly, the physiological conse-
quences of manipulating ghrelin signaling may vary
according to metabolic status. For example, Sun et al. * Correspondence: bgeddes@proteostasis.com
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f a td i e t( L F D )r e s p o n dt oag l u c o s ec h a l l e n g ew i t h
improved glucose disposal resulting from increased insu-
lin secretion, relative to WT littermates. In contrast,
under conditions of metabolic stress such as high fat
diet (HFD)-feeding, ghrelin-deficient mice have
improved glucose homeostasis characterized by signifi-
cantly lower fasting serum insulin levels [5]. Consistent
with this latter observation, we have previously observed
that HFD-fed GhrR KO mice have improved insulin sen-
sitivity corresponding with a striking reduction in the
insulin required for glucose disposal in response to a
glucose challenge [2].
In the current series of experiments we performed
hyperglycemic clamps in HFD-fed GhrR KO mice in
order to examine both insulin sensitivity and the
dynamics of insulin secretion in response to a glucose
challenge. To further understand the mechanism by
which blockade of ghrelin receptor signaling improves
insulin sensitivity under conditions of metabolic stress,
we also performed a hyperinsulinemic-euglycemic clamp
in GhrR KO mice fed a HFD and determined tissue glu-
cose dynamics. Our results clearly demonstrate that loss
of signaling through the GhrR improves insulin sensitiv-
ity under conditions of HFD-induced metabolic stress.
This insulin sensitivity is characterized by a decreased
insulin requirement in the face of a glucose challenge.
Additionally, our results reveal a role of hepatic insulin
sensitivity in the phenotype of GhrR KO mice.
Results
In preliminary evaluations, GhrR KO mice showed
improved insulin sensitivity on both low and HFD [2,4].
The fasting blood glucose was 65.5 ± 4.5 vs. 78.4 ± 3.9
mg/dl (p < 0.05) on LFD, and 107.7 ± 3.9 vs. 118.2 ±
7.4 mg/dl on HFD in GhrR KO mice and WT mice,
respectively (data not shown). The corresponding fasting
plasma insulin was 0.66 ± 0.07 vs. 0.77 ± 0.08 ng/ml on
LFD, and 0.76 ± 0.09 vs. 1.41 ± 0.32 ng/ml (p < 0.05)
on HFD in GhrR KO and WT mice, respectively (data
not shown).
Hyperglycemic clamp
To evaluate the effects of HFD on islet ß-cell function
we performed the HG clamp. This assay allows for the
evaluation of glucose-stimulated insulin secretion (GSIS)
to an initial glucose challenge. Initial experiments com-
paring diet-induced obese (DIO) vs lean mice confirmed
the ability of this assay to reveal the relative insulin
resistance of DIO mice relative to lean controls (Figure
1). The pre-study fasted body weight of the DIO mice
(45.57 ± 0.96) was significantly greater than the chow-
fed littermates (33.46 ± 1.33). Using the identical experi-
mental paradigm, we observed no significant differences
in GSIS of GhrR KO mice compared with WT animals
at either 1 min (2.09 ± 0.41 vs 1.31 ± 0.15 ng/mL) or
5 min (1.88 ± 0.40 vs 1.20 ± 0.15 ng/mL) after the initial
glucose challenge (Figure 2A). The HG clamp experi-
ments thus highlight that in GhrR KO mice the ß-cell
Figure 1 Hyperglycemic (HG) clamp in anesthetized DIO and
lean mice. The HG clamps were performed over a 90 min period
as previously described [29], with the exception of modifications
described in the methods section. The hyperglycemic target was
300 mg/dl. Changes in plasma insulin concentration during HG
clamp: first phase (A) and second phase (B); glucose infusion rate
(C). Data are the means ± SE n = 6-8/group. *p < 0.05 vs. lean mice.
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during the second phase of the experiment WT mice
required more insulin to maintain steady state hypergly-
cemia relative to GhrR KO mice, reaching statistical
significance at the 70 min (5.72 ± 1.40 vs 2.41 ± 0.32
ng/mL) and 90 min (6.14 ± 1.50 vs 2.90 ± 0.34 ng/mL)
time points (Figure 2B). Moreover, the GIR was signifi-
cantly higher in KO mice compared to WT (7.76 ± 1.65
vs 5.68 ± 1.52 mg/kg/min, Figure 2C), indicative of
increased insulin sensitivity of the GhrR KO mice. GhrR
KO mice, therefore, have increased insulin sensitivity
characterized by a decreased insulin requirement for
glucose disposal relative to WT controls. Prior to initiat-
ing the clamp experiment, there was a statistically signif-
icant difference in fasted body weight (BW) of GhrR KO
mice versus WT controls (40.99 ± 1.28 vs 45.07 ± 1.27,
respectively). Thus, in this experiment the reduced BW
of the GhrR KO mice will have contributed to the over-
all improvement in their insulin sensitivity.
Hyperinsulinemic-euglycemic clamp
We next evaluated hepatic insulin sensitivity and insu-
lin-mediated glucose disposal HFD- and LFD-fed male
GhrR KO and WT mice (Figure 3). Prior to the study,
fasted BW of LFD-fed GhrR KO mice (24.86 ± 0.67)
was significantly less than WT controls (29.7 ± 1.63).
However, in the HFD-fed groups, while there was a
trend toward reduced BW in the GhrR KO mice (43.90
± 1.21), it was not statistically significant versus WT
(47.91 ± 1.37). Significant increases in the GIR of LFD-
fed GhrR KO mice (41.0 ± 1.4 mg/kg/min) vs WT litter-
mates (33.1 ± 2.1 mg/kg/min) as well as HFD-fed GhrR
KO mice (29.1 ± 2.1 mg/kg/min) vs WT (22.0 ± 2.3
mg/kg/min) were observed (Figure 3A). Consistent with
this, glucose disposal (Rd) was significantly enhanced in
GhrR KO mice (Figure 3B). HGP (Figure 3C) was signif-
icantly reduced in GhrR KO vs WT littermates on either
a LFD (0.12 ± 0.09 vs. 0.57 ± 0.15 mg/kg/min) or HFD
(-0.14 ± 0.32 vs. 1.2 ± 0.41 mg/kg/min). Furthermore,
the enhancement of Rd seen in GhrR KO mice was
associated with significantly increased glucose uptake in
6 out of 8 tissues tested (WAT, BAT, gastrocnemius,
soleus, diaphragm and cerebral cortex; see Figure 4).
The trend of increased glucose uptake in tissues of
GhrR KO mice relative to WT controls failed to reach
statistical significance for hypothalamus and heart.
These results are consistent with the enhanced insulin
sensitivity previously observed in conscious HFD-fed
GhrR KO mice [2]. While differences in BW will have
contributed to the insulin sensitivity observed in the
LFD-fed KO mice, based on the data obtained in the
HFD-fed group it is equally clear that BW is not the
only factor involved in the insulin sensitivity of GhrR
KO mice.
Increased hepatic insulin sensitivity of conscious GhrR KO
in a pyruvate tolerance test (PTT)
To confirm the reduced HGP of HFD-fed GhrR KO
mice observed in the clamp study, we conducted a
Figure 2 Hyperglycemic (HG) clamp in anesthetized HFD-fed
GhrR KO and WT mice. The HG clamps were performed over a 90
min period as previously described [29], with the exception of
modifications described in the methods section. The hyperglycemic
target was 300 mg/dl. Changes in plasma insulin concentration
during HG clamp: first phase (A) and second phase (B); glucose
infusion rate (C). Data are the means ± SE n = 8-10/group.
*p < 0.05 vs. WT mice.
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ences in fasted BW between GhrR KO and WT mice fed
a HFD (47.63 ± 1.36 and 48.78 ± 1.28, respectively).
HFD-fed GhrR KO mice had lower plasma glucose levels
measured at 15 and 30 minutes after administration of
the gluconeogenic substrate pyruvate (Figure 5, p < 0.05),
indicative of reduced hepatic glucose output.
Effects of GhrR KO on UCP1 and UCP2 mRNA expression
in response to HFD
UCP2 is a fatty acid-responsive mitochondrial inner mem-
brane carrier protein showing wide tissue distribution, but
with a substantially increased presence in fatty liver. In
comparison with lean animals, hepatic gene expression of
UCP2 is increased in ob/ob mice and DIO rats [11,12].
Increased UCP2 expression in steatotic liver appears to
play a reactive and protective role in limiting oxidative
damage associated with increased fatty-acid oxidation
[13-16]. In the present study GhrR KO mice fed a HFD
showed significantly reduced UCP2 expression relative to
HFD-fed WT mice (Figure 6A), consistent with the
decreased hepatic steatosis in HFD-fed GhrR KO mice [2].
UCP1 functions in BAT to uncouple substrate oxida-
tion from ATP production leading to the generation of
Figure 3 Hyperinsulinemic-euglycemic clamp in both low and
high fat diet GhrR KO mice. (A) Glucose infusion rate. (B) Rate of
glucose disposal. (C) Hepatic glucose production. Data are means ±
SE from 9-10 mice per group. *, p < 0.05; **, p < 0.01 (GhrR KO vs.
WT). GIR, glucose infusion rate; Rd, rate of glucose disposal; HPG,
hepatic glucose production.
Figure 4 Tissue glucose uptake in HFD-fed mice of
hyperinsulinemic-euglycemic clamp. At the termination of the HI-
clamp, tissues were collected from GhrR KO and WT mice (n = 9-10
mice per group) and frozen until analysis. Data are means ± SE.
*, p < 0.05 (GhrR KO vs. WT). WAT, white adipose tissue; BAT, brown
adipose tissue.
Qi et al. BMC Physiology 2011, 11:1
http://www.biomedcentral.com/1472-6793/11/1
Page 4 of 8heat [17]. We measured BAT UCP1 expression to deter-
mine if the increased BAT glucose uptake may lead to
increased thermogenesis. In contrast to liver-UCP2,
there was no change in BAT-UCP1 mRNA expression
in HFD-fed GhrR KO mice (Figure 6B).
Discussion
Ghrelin and its receptor play an important role in the
regulation of glucose homeostasis. Both ghrelin KO and
GhrR KO mice demonstrate a lower fasting blood glucose
with reduced corresponding plasma insulin relative to
wild type littermates when fed a HFD [2,5], suggesting
that ablation of ghrelin signaling improves insulin sensi-
tivity. In the present studies, we have further character-
ized the degree and nature of the insulin sensitivity in
GhrR KO mice in both hyperglycemic and hyperinsuline-
mic-euglycemic clamp assays. Obviously, decreases in
body weight will lead to improvements in glucose home-
ostasis. However, while there was a tendency for the
HFD-fed GhrR KO mice to have reduced BW (~5 g) rela-
tive to WT controls, this was not always the case. Our
lab has evaluated dozens of HFD-fed GhrRKO mouse
cohorts over the course of roughly 5 years of experiment-
ing with this model. In so doing we have documented a
degree of variability in the BW response to HFD from
cohort to cohort such that we occasionally observe non-
significant differences between groups. That variability is
reflected in the data described in the present work and
most likely indicates physiological variability one would
expect to see upon repeated testing over the course of a
year. However, despite the variability of the BW
responses in GhrR KO mouse cohorts, the reported
pattern of insulin sensitivity characterized by significantly
reduced insulin release coupled with improved glucose
disposal is always present. Thus, while not investigated
explicitly in these experiments, our data reveal that there
is a BW-independent component to the improved insulin
sensitivity of GhrR KO mice. Further, we provide evi-
dence from HI-clamp, PTT and expression data that sug-
gests an hepatic mechanism for GhrR KO insulin
sensitivity. Clearly, decreases in BW contribute to the
overall improved insulin sensitivity of HFD-fed GhrR KO
mice, but it is not the only factor.
Our lab has demonstrated previously that GhrR KO
mice fed HFD require less insulin for glucose disposal
relative to WT controls during a GTT [2]. We therefore
Figure 5 Pyruvate tolerance test of HFD-fed GhrR KO and WT
mice. Overnight fasted HFD-fed GhrR KO and WT mice each
received an i.p. injection of 1 g/kg sodium pyruvate dissolved in
water. Tail vein blood glucose samples were assessed for glucose
concentration immediately before injection (time 0) and at the
indicated time points post-injection. n = 10 mice per group. Data
are means ± SE. *, p < 0.05 (GhrR KO vs. WT).
Figure 6 UCP2 and UCP1 expression levels in liver and BAT,
respectively. (A) mRNA expression of UCP2 of liver in overnight
fasted HFD-fed mice. n = 5 mice per group. (B) mRNA expression of
UCP1 of BAT in overnight fasted HFD-fed mice. n = 5 mice per
group. Data are means ± SE. *p < 0.05 (GhrR KO vs. WT). UCP,
uncoupling protein.
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animals in more detail. The GhrR KO mice fed a HFD
responded to the initial glucose priming dose with a
robust first-phase release of insulin that was not signifi-
cantly different than WT controls, indicating no deficit in
their ability to secrete insulin upon challenge [18]. How-
ever, a relative trend of decreased insulin requirement of
GhrR KO mice was maintained throughout the 2
nd phase
of insulin release [18], and reaching its maximal effect at
the point of HG clamp. This pattern is consistent with
previous data obtained during a GTT in HFD-fed GhrR
KO mice (2). Indeed, GhrR KO mice fed a HFD are more
insulin sensitive compared to WT mice as determined by
their significantly increased GIR during the HG clamp.
Furthermore GhrR KO mice showed decreased HGP,
increased glucose disposal and increased tissue glucose
uptake in HI-E clamp studies. Remarkably, these effects
could be discerned regardless of whether mice were fed a
LFD or HFD. In contrast, LFD-fed ghrelin-deficient mice
responded to a glucose challenge with increased insulin
secretion [3]. The reasons for this apparent dichotomy
may be a reflection of differences in islet glucose sensing
as a result of chronic exposure to high plasma FFA [19]
caused by the HFD. Thus, unlike glucose responsiveness,
the underlying improvements of insulin sensitivity result-
ing from blockade of GhrR signaling do not appear to be
affected by diet.
In order to understand the mechanism underlying
improved hepatic insulin sensitivity, we evaluated hepa-
tic insulin sensitivity of HFD-fed GhrR KO mice with a
pyruvate tolerance test (PTT), which measures the capa-
city of the liver to convert pyruvate to glucose, a process
that would normally be inhibited by insulin. In compari-
son to WT control mice, GhrR KO mice had a signifi-
cantly lower gluconeogenic response to the pyruvate
challenge, consistent with their relative insulin sensitiv-
ity. Therefore, blockade of GhrR signaling does not
appear to interfere with gluconeogenesis, but rather may
decrease HGP via an alternative mechanism, possibly as
a secondary result of decreased hepatic lipid burden (2).
Hyperinsulinemia is associated with hepatic steatosis
and hyperlipidemia in humans and animal models
[20-22], and treatment with insulin-sensitizing drugs
ameliorates these conditions [21,23]. Increased fatty acid
levels lead to elevations in hepatic UCP2 expression in
rats [24], and the circulating free fatty acid concentra-
tion correlates with UCP2 expression in white fat and
skeletal muscle [25], suggesting that UCP2 is important
for the metabolic adaptation of these tissues to excessive
fatty acid. Both GhrR and ghrelin KO mice have
improved plasma lipid profiles relative to WT mice on a
HFD [2,5]. GhrR KO mice have higher fatty acid oxida-
tion and lower lipogenesis, as evidenced by improved
hepatic steatosis and lower intestinal triglyceride
secretion rate when exposed to HFD [2]. Ghrelin defi-
ciency has been associated previously with a decrease in
mitochondrial UCP2 mRNA expression in the livers of
chow-fed mice [3]. Likewise, in the present study hepa-
t i ce x p r e s s i o no fU C P 2m R N Aw a sl o w e ri nH F D - f e d
GhrR KO mice. Taken together, our results suggest that
lower expression of UCP2 mRNA of liver reflects
improved lipid metabolism in HFD-fed GhrR KO mice
and likely contributes to the overall insulin sensitivity in
these animals.
Our observation that GhrR KO mice had increased
glucose uptake into BAT suggested that increased glu-
cose utilization in this tissue may contribute to the
improved metabolic phenotype of these mice via
increased fatty acid oxidation. BAT is a thermogenic
organ in which increased expression of UCP1 decreases
mitochondrial energy efficiency, leading to the genera-
tion of heat [17]. However, the impact of GhrR signaling
on thermogenesis is not yet clear. To investigate
whether the improved glucose uptake in BAT is asso-
ciated with increased thermogenesis in GhrR KO mice
consuming HFD, we measured UCP1 mRNA expression
in BAT. We previously reported that GhrR deletion in
mice had no effect on total energy expenditure [2],
which was consistent with the finding that injection of
ghrelin had no effect on energy expenditure in rats [8].
In another study, however, central administration of
ghrelin suppressed energy expenditure and thermogen-
esis in BAT via an inhibitory effect on BAT sympathetic
nerve activity [26,27]. In the current study, BAT UCP1
mRNA expression was unaffected by genotype in HFD-
fed mice, which indicated that diet-induced thermogen-
esis was not impacted by the loss of ghrelin signaling.
Conclusions
In summary, these data provide further compelling evi-
dence that blockade of the GhrR improves insulin sensi-
tivity. This effect in HFD-fed GhrR KO mice has now
been demonstrated using the GTT, PTT, HG-clamp and
HI-E clamp assays. Furthermore, the characteristic
decrease in the insulin required for glucose disposal in
GhrR KO mice, originally demonstrated in GTT experi-
ments, has been confirmed in HG clamps. The insulin
sensitivity of these mice was confirmed by the observa-
tion of increased glucose uptake by peripheral tissue
during HI-clamp. Thus, we provide evidence for hepatic
insulin sensitivity as a contributing factor to the overall
insulin sensitivity observed in the GhrR KO mice.
Whether hepatic insulin sensitivity contributes to, or is
secondary to reduced hepatic steatosis was not deter-
mined in these studies. GhrR KO mice have decreased
HGP in both the HI-clamp and PTT. Consistent with
these observations we found elevated UCP2 expression
levels in the livers of HFD-fed GhrR KO mice. These
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improvements associated with blockade of GhrR signal-
ing and substantiate the therapeutic potential of GhrR
antagonists in the treatment of metabolic diseases, such
as type 2 diabetes.
Methods
Animals
The GhrR KO animals used in these studies were bred
f r o mas i n g l ef o u n d e rm o u s ea tt h eC h a r l e sR i v e r
Laboratories (Wilmington, MA) [28]. GhrR +/- mice on
the C57BL/6 genetic background (N4) were bred to pro-
duce homozygous null and wild type littermate controls.
Mice were genotyped as described [2]. Mice were
housed in controlled environment rooms (72°F, ~40%
humidity, 12 h/12 h in-phase light/dark cycles at 6 am/6
pm) in ventilated racks (Thoren; Hazelton, PA). All
mice had ad libitum access to normal chow from wean-
ing (PicoLab rodent diet 20, Purina; St. Louis, MO).
Diet-induced obesity (DIO) was generated in mice by
giving ad libitum access to a 60% kcal fat diet (D12492,
Research Diets; Rahway, NJ) starting at eight weeks of
age, for at least 4 months. In all experiments, pre-study
BW was measured the morning after an overnight fast
(maximum 16 hours). The work described herein
involved the use of several independent cohorts of GhrR
KO and WT mice over the course of two years. Experi-
mental procedures were in accordance with regulations
of the Elixir Pharmaceuticals Institutional Animal Care
and Use Committee.
Hyperglycemic clamp
The HG clamps were performed over a 90 min period
as previously described [29], with the following modifi-
cations. During the entire procedure, the animals were
kept warm using a heating pad. Tail blood samples (25
μl) were removed at 0 (baseline), 1 and 5 min after a
priming intravenous injection of 50% glucose (0.25 g/
kg), for the measurement of first phase blood glucose
and plasma insulin. Immediately after the 5 min sam-
pling time point animals received an infusion of 20%
glucose. Tail blood glucose readings were taken at 5-10
min intervals thereafter and the 20% glucose infusion
rate was adjusted in order to reach, and then maintain,
blood glucose levels at approximately 300 mg/dl.
Twenty-five μl blood samples were collected via the car-
otid artery at 20, 50, 70 and 90 min after baseline for
plasma insulin determination. During the 50-90 min
time points, steady state hyperglycemia was established
(3 consecutive readings of 300 mg/dl) at which time the
GIR was determined. Preliminary experiments were per-
formed comparing diet-induced obese (DIO) vs lean
mice prior to conducting experiments on HFD-fed GhrR
KO vs WT mice (Figure 1).
Hyperinsulinemic-euglycemic (HI-E) clamp
30-week-old HFD- and LFD-fed male mice were fasted
overnight (16-18 h), anesthetized with sodium pentobar-
bital (50 mg/kg, i.p.), before undergoing a hyperinsuline-
mic-euglycemic clamp as previously described [30].
During the entire procedure, the animals were kept
warm using a heating pad. Thirty min after the right
internal jugular vein cannulation, mice underwent the
hyperinsulinemic-euglycemic (HI) clamp for 120 min-
utes. A second dose of anesthetic (10 mg/kg, i.p.) was
delivered 30 minutes after the start of the clamp and
mice were maintained under anesthesia for the duration
of the experiment. A priming dose of human insulin
(100 mU/kg, iv; Humulin R; Eli Lilly, Indianapolis, IN)
was administered, followed by continuous iv infusion at
50 mU/kg/min. Tail blood samples (4 μl) were collected
at 10 min intervals for measurement of glucose (Ascen-
sia Elite glucometer, Bayer, Indianapolis, IN), and 20%
glucose was infused to maintain blood glucose between
110 and 140 mg/dl. Insulin-stimulated whole body glu-
cose disposal was assessed using a priming injection of
5-μCi HPLC-purified [3-
3H] glucose (Perkin Elmer, Bos-
ton, MA) followed by continuous infusion at 0.05 μCi/
min throughout the study; Once steady state was
attained for 30 minutes, a bolus of 10 μCi 2-deoxy-D-
[1-
14C] glucose (Perkin Elmer, Boston, MA) was injected
intravenously (minute 75) to determine the insulin-sti-
mulated glucose uptake of various tissues. Insulin was
measured in 10 μl blood samples drawn before cannula-
tion surgery and at the end of clamps. The mice were
killed at the end of the experiment, and muscles, perigo-
nadal white adipose tissue, and liver were harvested, fro-
z e ni nl i q u i dn i t r o g e n ,a n ds t o r e da t- 8 0 ° Cu n t i l
processing. The glucose infusion rate (GIR), HGP, rate
of glucose disposal (Rd), and tissue glucose uptake were
determined as previously described [31,32].
Pyruvate tolerance test (PTT)
30-week-old, HFD-fed male mice were fasted overnight
(16-18 h), before undergoing a PTT as previously
described [33]. GhrR KO mice and wild type littermates
each received an i.p. injection of 1 g/kg sodium pyruvate
dissolved in water. Tail-vein blood samples were
assessed for glucose immediately before injection (time
0) and at 15, 30 and 60 minutes post-injection.
RNA preparation and Real time (RT) PCR
Total RNA of flash-frozen liver and BAT from overnight
fasted mice was extracted using TRIzol reagent (Invitro-
gen). The mRNA of PEPCK, G-6-Pase and UCP-2 in
liver, and mRNA of UCP-1 in BAT were analyzed by
real time PCR and normalized to a housekeeping gene
(36B4) (Light Cycler 480 SYBR Green, Roche Diagnos-
tics, Indianapolis, IN).
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Plasma insulin was measured by a homogeneous time-
resolved fluorescence immunoassay (HTRF) (Cisbio-US,
Inc, Bedford, MA).
Statistical analyses of data
All values are expressed as the mean ± SE. Changes in
various parameters were analyzed by two-way ANOVA
and pair-wise differences assessed using Bonferroni
post-hoc tests (GraphPad Prism, San Diego, CA). We
compared end-of-study values using the Student’s t-test.
P < 0.05 was considered significant.
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